ID: MRFR/MED/4827-HCR | February 2021 | Region: Global | 100 Pages
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porterβs Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Breast Biopsy Market, by Product
6.1 Introduction
6.2 Biopsy Needles
6.3 Biopsy Tables
6.4 Biopsy Wires
6.5 Guidance Systems
6.6 Others
Chapter 7. Global Breast Biopsy market, by Technique Type
7.1 Introduction
7.2 Fine Needle Aspiration Biopsy
7.3 Core Needle Biopsy
7.3.1 Stereotactic Core Needle Biopsy
7.3.2 Vacuum Assisted Biopsies
7.3.3 Ultrasound Guided Core Biopsy
7.3.4 Freehand Needle Biopsy
7.4 Biopsy Markers
7.5 MRI-Guided Core Needle Biopsy
7.6 Surgical Biopsy
7.6.1 Incisional Biopsy
7.6.2 Excisional Biopsy
7.7 Wire Localization
7.8 Sentinel Node Biopsy
Chapter 8. Global Breast Biopsy Market, by Guidance Technology
8.1 Introduction
8.2 Fine Ultrasound-Guided
8.3 Mammography-Guided magnetic resonance
8.4 CT-Guided Biopsy
8.5 Other Image-Guided Breast Biopsy (PET and thermography)
Chapter 9 Global Breast Biopsy Market, by End-User
9.1 Introduction
9.2 Hospitals
9.3 Ambulatory Surgical Centers
9.4 Diagnostic Centers
9.5 Other
Chapter 10. Global Breast Biopsy Market, by Region
10.1 Introduction
10.2 America
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11. Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Becton, Dickinson and Company
12.1.1 Company Overview
12.1.2 Type Overview
12.1.3 Financials
12.2.4 Key Developments
12.1.5 SWOT Analysis
12.2 C.R. Bard, Inc.
12.2.1 Company Overview
12.2.2 Type Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Devicor Medical Products Inc.
12.3.1 Company Overview
12.3.2 Type Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Hologic Inc.
12.4.1 Company Overview
12.4.2 Type/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Argon Medical Devices
12.5.1 Company Overview
12.5.2 Type Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Cook Medical Incorporated
12.6.1 Company Overview
12.6.2 Type Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Encapsule Medical Devices LLC.
12.7.1 Overview
12.7.2 Type Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Johnson & Johnson
12.8.1 Overview
12.8.2 Type Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Galini SRL
12.9.1 Overview
12.9.2 Type Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Intact Medical Corporation
12.10.1 Overview
12.10.2 Type Overview
12.10.3 Financials
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.11 CONCEPTUS INC
12.11.1 Overview
12.11.2 Type Overview
12.11.3 Financials
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.12 Hologic Inc.,
12.12.1 Overview
12.12.2 Type Overview
12.12.3 Financials
12.12.4 Key Developments
12.12.5 SWOT Analysis
12.13 Karl Storz GmbH & Co. Kg
12.13.1 Overview
12.13.2 Type Overview
12.13.3 Financials
12.13.4 Key Developments
12.13.5 SWOT Analysis
12.14 GE Healthcare
12.14.1 Overview
12.14.2 Type Overview
12.14.3 Financials
12.14.4 Key Developments
12.14.5 SWOT Analysis
12.15 Others
Chapter 13 Appendix
LIST OF TABLES
Table 1 Breast Biopsy Market Industry Synopsis, 2018β2023
Table 2 Global Breast Biopsy Market Estimates & Forecast, 2018β2023, (USD Million)
Table 3 Global Breast Biopsy Market, by Region, 2018β2023, (USD Million)
Table 4 Global Breast Biopsy Market, by Diagnosis, 2018β2023, (USD Million)
Table 5 Global Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 6 Global Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
Table 7 North America: Breast Biopsy Market, by Diagnosis, 2018β2023, (USD Million)
Table 8 North America: Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 9 North America: Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
Table 10 US: Breast Biopsy Market, by Diagnosis, 2018β2023, (USD Million)
Table 11 US: Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 12 US: Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
Table 13 Canada: Breast Biopsy Market, by Diagnosis, 2018β2023, (USD Million)
Table 14 Canada: Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 15 Canada: Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
Table 16 South America: Breast Biopsy Market, by Diagnosis, 2018β2023, (USD Million)
Table 17 South America: Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 18 South America: Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
Table 19 Europe: Breast Biopsy Market, Diagnosis, 2018β2023, (USD Million)
Table 20 Europe: Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 21 Europe: Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
Table 22 Western Europe: Breast Biopsy Market, by Diagnosis, 2018β2023, (USD Million)
Table 23 Western Europe: Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 24 Western Europe: Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
Table 25 Eastern Europe: Breast Biopsy Market, by Diagnosis, 2018β2023, (USD Million)
Table26 Eastern Europe: Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 27 Eastern Europe: Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
Table 28 Asia-Pacific Breast Biopsy Market, by Diagnosis, 2018β2023, (USD Million)
Table 29 Asia-Pacific: Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 30 Asia-Pacific: Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
Table 31 Middle East & Africa: Breast Biopsy Market, by Diagnosis, 2018β2023, (USD Million)
Table 32 Middle East & Africa: Breast Biopsy Market, by Treatment, 2018β2023, (USD Million)
Table 33 Middle East & Africa: Breast Biopsy Market, by End-User, 2018β2023, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Breast Biopsy Market
Figure 3 Market Dynamics for Global Breast Biopsy Market
Figure 4 Global Breast Biopsy Market Share, by Diagnosis 2020
Figure 5 Global Breast Biopsy Market Share, by Treatment 2020
Figure 6 Global Breast Biopsy Market Share, by End-User, 2020
Figure 7 Global Breast Biopsy Market Share, by Region, 2020
Figure 8 North America: Breast Biopsy Market Share, by Country, 2020
Figure 9 Europe: Breast Biopsy Market Share, by Country, 2020
Figure 10 Asia-Pacific: Breast Biopsy Market Share, by Country, 2020
Figure 11 Middle East & Africa: Breast Biopsy Market Share, by Country, 2020
Figure 12 Global Breast Biopsy Market: Company Share Analysis, 2020 (%)
Figure 13 PFIZER INC: Key Financials
Figure 14 PFIZER INC: Segmental Revenue
Figure 15 PFIZER INC: Geographical Revenue
Figure 16 Koninklijke Philips N.V: Key Financials
Figure 17 Koninklijke Philips N.V: Segmental Revenue
Figure 18 Koninklijke Philips N.V: Geographical Revenue
Figure 19 Boston Scientific Corporation: Key Financials
Figure 20 Boston Scientific Corporation: Segmental Revenue
Figure 21 Boston Scientific Corporation: Geographical Revenue
Figure 22 LUPIN: Key Financials
Figure 23 LUPIN: Segmental Revenue
Figure 24 LUPIN: Geographical Revenue
Figure 25 Bayer AG: Key Financials
Figure 26 Bayer AG: Segmental Revenue
Figure 27 Bayer AG: Geographical Revenue
Figure 28 PHYTON: Key Financials
Figure 29 PHYTON: Segmental Revenue
Figure 30 PHYTON: Geographical Revenue
Figure 31 CELGENE CORPORATION. : Key Financials
Figure 32 CELGENE CORPORATION. : Segmental Revenue
Figure 33 CELGENE CORPORATION. : Geographical Revenue
Figure 34 Johnson & Johnson: Key Financials
Figure 35 Johnson & Johnson: Segmental Revenue
Figure 36 Johnson & Johnson: Geographical Revenue
Figure 37 CooperSurgical Inc.: Key Financials
Figure 38 CooperSurgical Inc.: Segmental Revenue
Figure 39 CooperSurgical Inc.: Geographical Revenue
Figure 40 LiNA Medical USA: Key Financials
Figure 41 LiNA Medical USA: Segmental Revenue
Figure 42 LiNA Medical USA: Geographical Revenue
Figure 46 Hologic Inc.: Key Financials
Figure 47 Hologic Inc.: Segmental Revenue
Figure 48 Hologic Inc.: Geographical Revenue
Figure 49 Karl Storz GmbH & Co. Kg: Key Financials
Figure 50 Karl Storz GmbH & Co. Kg: Segmental Revenue
Figure 51 Karl Storz GmbH & Co. Kg: Geographical Revenue
Figure 52 C.R. Bard: Key Financials
Figure 53 C.R. Bard: Segmental Revenue
Figure 54 C.R. Bard: Geographical Revenue
Figure 55 GE Healthcare: Key Financials
Figure 56 GE Healthcare: Segmental Revenue
Figure 57 GE Healthcare: Geographical Revenue
$1104 million
10.10%
North America,Europe,Asia-Pacific
2020-2027
The breast biopsy market is projected to reach USD 1104 million by 2027 at CAGR of 10.10%. A breast biopsy is a procedure usually done after mammography or ultrasound, only when a suspicious lesion or hard palpable lump is discovered in any of those test processes. The breast biopsy removes a sample of that suspicious tissue and is then sent to the pathologists to analyze the tissue. Palpable lumps and abnormalities can be discovered by physical, self-examination, or mammography; however such procedures can’t determine the abnormal growth is benign or cancerous. A breast biopsy is usually suggested when the doctor identifies a lump or thickening of the patient’s breast, or if the mammogram identifies a suspicious tissue in the patient’s breast. Therefore Breast Biopsy is not the initial procedure.
During the Biopsy, the loud clicking sound will be heard while the sample is collected from the patient’s body. The physician might move the needle around the suspicious area to collect the sample from different parts and collect about 8 samples for various test procedures. There are varied types in the biopsy procedures, most of which are minimally invasive procedures. The increasing prevalence of breast cancer cases across the globe and the minimally invasive procedure are driving the Breast Biopsy market growth in recent times.
COVID 19 Analysis:
Several surgical plans have been postponed due to the widespread of COVID. Since surgical procedures tend to increase the chances of getting an infection, surgeons have had to make difficult decisions to postpone elective surgeries. Additionally, the health care centers had to find alternative pathways to treat patients who are diagnosed with cancer or cancer suspects, since the cancer patients are more vulnerable to get affected by COVID.
Limited access to clinical centers, social distancing, and strict guidelines throughout the globe has significantly affected the growth of the Breast biopsy market. Potential delays in the cancer diagnosis or treatment could lead to life-threatening conditions and had to be balanced during the pandemic due to the risk of exposure to COVID infection. This factor was the major challenge during the early stages of the pandemic.
Market Dynamics:
Drivers:
Novel biopsy technique and the advent of new product approvals provides minimally invasive procedures. A 6mm Bergstrom side-cutting biopsy needle was considered as a successful instrument to obtain large pieces of tissue, under the guidance of ultrasound. Such new instruments and techniques have significantly impacted the overall growth of the Breast biopsy market.
Increasing incidences of breast cancer in recent years is the primary growth attributing factor for the Breast biopsy market. Over 265,000 cancer susceptive cases were diagnosed in the year 2018 and over 63,960 non-invasive procedures were carried out during the year. Such reports are stimulating the overall growth of the market.
Market opportunities:
Identifying cancer cells and DNA fragments have been a challenge in the medical industry, the advent of liquid biopsy has helped medical practitioners in identifying the circulating tumor cells precisely. Moreover, the necessity of surgeries and adverse effects of the surgeries such as scars could be eliminated with the process. The liquid biopsy can identify all of the genetic complexity of the tumors present in human breasts and is also capable of stopping them from spreading to other parts of the body. Such attractive features of the liquid biopsy have presented a lucrative opportunity for the overall Breast Biopsy Market growth.
The invasive procedures have brought in several adverse effects such as huge blood loss, surgical infection, and longer recovery time. However, the advent of minimally invasive alternatives such as image-guided biopsy has given accurate results. The increase in acceptance of image-guided needle biopsy is expected to drive the Breast Biopsy market growth in the forecast period.
Market restraints:
The surgical procedure in the biopsy tests carries adverse effects such as bruising the breasts, swelling, soreness, and post-surgery infection in the operated site. Some of the signs of infections such as warmth in breasts discharge from the site, redness in the site, or fever of over 100’f might be ignored by the patient which might take the situation to serious condition. Such factors are hindering the Breast biopsy market growth.
Some over-the-counter drugs have to be avoided post-surgery, herbs, drugs, vitamin or mineral drugs might contradict the medication administered during the biopsy. If the patient has not followed the advice of the medical practitioner, the condition gets worse. Such factors are considered as major restraining factors for the overall growth of the Breast biopsy market.
Market challenges:
Some developing countries possess poor treatment facilities, especially concerning cancer-related treatments. Poor health infrastructure in some countries, lack of skilled surgeons, and lack of essential resources are projected as major challenges for the Breast Biopsy market growth. A recent study shows that there would be a shortage of over 2300 medical oncologists in the US by the year 2025 while comparing with the rising cancer incidences.
Inadequate obtaining of tissue could make the entire process worthless, and possible false negative indications are some of the major restraining factors for the growth of the Breast biopsy market.
Cumulative growth analysis:
The advent of liquid biopsy has created a new dimension in the field of oncology. The liquid biopsy comes with several advantages over the tissue biopsy procedure. They are minimally invasive, therefore comes with minimal complications or adverse effects. Since the medical instrument utilized in the liquid biopsy is easier to handle, the process requires minimal medical skill and can be repeated when necessary. Moreover, the combination of droplet digital PCR technology and NGS-based assays has augmented the Breast Biopsy market growth in several countries.
The Breast Biopsy market value was at USD 1123 million in the year 2019, owing to the increasing prevalence of cancer patients and increased mortality rate due to breast cancer, the market value is expected to surpass over USD 1890 million by the year 2026 while registering a CAGR of 6%. Despite the challenges imposed due to the COVID infection spread, the alternative medical facilities have managed to favor the growth of the Breast biopsy market in recent times.
Value chain analysis:
There are a few options in the Biopsy procedures; the physician might choose the appropriate procedure according to the patient’s condition. If the patient is diagnosed with fluid-filled cysts in the breasts or nodules, or enlarged lymph nodes, the doctor might suggest a fine needle biopsy that is capable of reaching deeper and draws the fluid from the cyst or tissue sample. As the needles are very thin, even thinner than the ones used for blood tests, they are extremely painless.
On the other hand, if the physician decides to obtain the core tissue of the tumor. The Core needle biopsy is carried out. After administrating local anesthesia, the process is carried out. The needle has to be pierced few times to obtain several parts of the tumor. Although the procedure might take time more than the fine needle biopsy, accurate results are obtained through the procedure. Such diverse availability of options in the field has presented a lucrative opportunity for the Breast Biopsy market growth in the forecast period. The advent of the Tri-axial needle and increased utilization of this type of needle has enabled the physicians to obtain a clearer image in the Ultrasound or CT scans. Moreover, the needles help the health care professionals to obtain the tissue without compressing it. Under the guidance of CT or Ultrasound, the processes have attained higher success rates.
Segment overview:
Based on Product:
Based on Type:
Based on Guidance:
Based on Application:
Based on End-user:
Regional analysis:
Over other countries, North America is currently dominating the market share, accounting for over 42% in the year 2020. The region was diagnosed with over 62% of breast cancer cases in recent times. The advancing medical infrastructure and technology have augmented the overall growth of the market in the region. Moreover, the increasing awareness of identifying the palpable lumps in breasts, early identification, and self-examination have also impacted the Breast Biopsy market growth.
The minimal invasive diagnosis and straightforward procedures have aided the growth of Breast Biopsy procedures. Several developed healthcare systems have obtained alternative treatment pathways owing to the restrictions imposed due to pandemics. 68% of the health care institutions in over 41 countries across the globe have recommended endocrine therapy in luminal A tumors.
Competitive landscape:
Recent developments:
Recently, a leading biopsy center has announced a novel blood-based testing method; the supreme accuracy of the method has enabled physicians to perform complex biopsies with few procedures. The procedure has been extremely helpful owing to its accuracy in monitoring HER2 alterations in patients who were diagnosed with metastatic breast cancer.
In the year 2019, a European medical center has received approval for the Brevera Biopsy system which comes with Corlumina imaging technology. The technology enhances the procedure and increases the accuracy with a real-time imaging technique. The patients have felt reduced anxiety during the procedure and feel extremely comfortable throughout the procedure.
Report overview:
This report has covered:
Report Attribute/Metric | Details |
---|---|
Market Size | 2027: 1104 Million |
CAGR | 2020-2027: 10.10% |
Base Year | 2019 |
Forecast Period | 2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Product, Technique Type, Guidance Technology, And End-User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Leica Biosystems, C.R. Bard Inc., NuVue Therapeutics, Argon Medical Devices, Inc., Becton, Dickinson and Company, Devicor Medical Products Inc. Hologic Inc. Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC., Johnson & Johnson, Galini SRL, Intact Medical Corporation, Conceptus INC, Hologic Inc., Karl Storz GmbH & Co. Kg, GE Healthcare |
Key Market Opportunities | Emergence of technologically-advanced and minimally invasive breast biopsy devices |
Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
North America is expected to lead the Breast Biopsy Market.
Rising prevalence of breast cancer and availability of technologically advanced devices are adding market growth.
High cost and risks may limit market growth.
End users of Breast Biopsy Market include diagnostic centers, ambulatory surgical centers, and hospitals.
Different strategies used by industry players to create a dominance in the Breast Biopsy Market include extensive R&D, mergers and acquisitions, collaborations, and strategic alliances.